



# Allergy School 2024

**Bilbao, Spain**

**19-21 September**

**Insect Venom Hypersensitivity  
and Mastocytosis**



 [EAACI.org](https://www.eaaci.org)

Thursday 19 September

EAACI Allergy School 2024

Thu 19 Sep  
12:00 - 14:00

**Registration**  
Break & Ceremony

Thu 19 Sep  
14:00 - 14:15

**Welcome and Introduction**  
Break & Ceremony

14:00 **Welcome and Introduction**  
A. Vega Castro (Guadalajara, Spain)

Thu 19 Sep  
14:15 - 15:45

**Session I: Exploring the link between Hymenoptera venom allergy and mast cell diseases**

Room 0D Lecture session

Chair : A. Vega Castro (Guadalajara, Spain), M. Ollert (Esch-sur-Alzette, Luxembourg)

To learn how to clearly identify mastocytosis patients that develop venom allergy, the clinical phenotype, and new treatments, and to know alpha tryptasemia and its relation to Hymenoptera venom allergy.

14:15 **Update in mast cell diseases – new drugs**  
I. Alvarez Twose (Toledo, Spain)

14:40 **Management of mastocytosis and HVA**  
P. Bonadonna (Verona, Italy)

15:05 **Hereditary alpha-tryptasemia (HAT) and Hymenoptera**  
D. González-Olano (Madrid, Spain)

15:30 **Q&A**

Thu 19 Sep  
15:45 - 16:15

**Coffee Break**  
Break & Ceremony

Thu 19 Sep  
16:15 - 17:15

## Session II: Exploring Hymenoptera venom allergy and immunotherapy: a comprehensive introduction

Room 0D Lecture session

Chair : E. Boni (Bologna, Italy), H. Oude Elberink (Haren, Netherlands)

To have a broad comprehensive view of HVA diagnosis tools and know-how of venom immunotherapy.

16:15 **A gold standard tool in diagnosis and treatment?**

G. Sturm (Graz, Austria)

16:40 **Early immunological responses in venom immunotherapy**

M. Ollert (Esch-sur-Alzette, Luxembourg)

17:05 **Q&A**

Thu 19 Sep

17:15 - 17:45

## Oral presentation session 1

Room 0D Oral Abstract Session

Chair : M. Martini (Ancona, Italy), T. Alfaya Arias (Madrid, Spain)

Best attendees' studies are chosen for exposure and discussion.

17:15 **Hymenoptera Venom Allergy in patients with Systemic Mastocytosis: the importance of specific IgE associated with skin tests**

OA1

17:25 **Prospective Comparison of the Efficacy of 3 month extended Venom Immunotherapy (VIT) Administration in Patients with Mastocytosis Versus Conventional Treatment**

OA2

17:35 **Selection of the best commercial immunotherapy through CAP Inhibition in patients with anaphylaxis due to Vespa velutina**

OA3

Thu 19 Sep

17:45 - 18:15

## Industry Session 1

Industry Session

Thu 19 Sep

18:30 - 19:30

## Welcome Reception

Break & Ceremony

 Friday 20 September

EAACI Allergy School 2024

Fri 20 Sep

08:30 - 10:00

**Session III – Advancing Hymenoptera venom allergy diagnosis: concepts, identification, and immunotherapy prescription**

Room 0D Lecture session

Chair : K. Spriggs (Parkville, Australia), C. Breynaert (Leuven, Belgium)

To improve HVA diagnosis through proper insect identification, to approach to get the best accuracy in diagnosis and to identify the main criteria for prescribing venom immunotherapy.

08:30

**Insect identification and behavior**

F.J. Ortiz Sánchez (La Cañada (Almería), Spain)

08:55

**Diagnostic algorithm**

M. Martini (Ancona, Italy)

09:20

**Key points to prescribe venom immunotherapy**

E. Boni (Bologna, Italy)

09:45

**Q&A**

Fri 20 Sep

10:00 - 10:30

**Industry session 2**

Industry Session

Fri 20 Sep

10:30 - 11:00

**Coffee Break**

Break &amp; Ceremony

Fri 20 Sep  
11:00 - 13:15

## Workshop Session 1. Topic 1: Venom products: adapting diagnosis and treatment

Room 0D Workshop Session

To handle venom products: new ones, supplies deficiency, to guarantee patient's treatment.

Participants will be divided into 3 groups, and sessions will run simultaneously in rotation across 3 rooms, so each attendee will attend each of the sessions.

**11:00**      **Venom products: adapting diagnosis and treatment**  
B.M. Bilò (Ancona, Italy), E. Boni (Bologna, Italy)

**11:40**      **Rotation time for participants**

**11:45**      **Venom products: adapting diagnosis and treatment**  
B.M. Bilò (Ancona, Italy), E. Boni (Bologna, Italy)

**12:25**      **Rotation time for participants**

**12:30**      **Venom products: adapting diagnosis and treatment**  
B.M. Bilò (Ancona, Italy), E. Boni (Bologna, Italy)

**13:10**      **End**

Fri 20 Sep  
11:00 - 13:15

## Workshop Session 1. Topic 2: Diagnostic approach in polysensitized patients

Room 3B Workshop Session

To point out the key aspects in the diagnosis of complex allergic patients.

Participants will be divided into 3 groups, and sessions will run simultaneously in rotation across 3 rooms, so each attendee will attend each of the sessions.

**11:00**      **Diagnostic approach in polysensitized patients**  
M. Martini (Ancona, Italy), G. Sturm (Graz, Austria)

**11:40**      **Rotation time for participants**

**11:45**      **Diagnostic approach in polysensitized patients**  
M. Martini (Ancona, Italy), G. Sturm (Graz, Austria)

**12:25**      **Rotation time for participants**

**12:30**      **Diagnostic approach in polysensitized patients**  
M. Martini (Ancona, Italy), G. Sturm (Graz, Austria)

**13:10**      **End**

Fri 20 Sep  
11:00 - 13:15

## Workshop Session 1. Topic 3: Sting challenge test

Room 3A Workshop Session

To learn how to perform sting challenges with live insects using simulated targets.

Participants will be divided into 3 groups, and sessions will run simultaneously in rotation across 3 rooms, so each attendee will attend each of the sessions.

**11:00**     **Sting challenge test**  
T. Alfaya Arias (Madrid, Spain), B. Ruíz-León (Córdoba, Spain)

**11:40**     **Rotation time for participants**

**11:45**     **Sting challenge test**  
T. Alfaya Arias (Madrid, Spain), B. Ruíz-León (Córdoba, Spain)

**12:25**     **Rotation time for participants**

**12:30**     **Sting challenge test**  
T. Alfaya Arias (Madrid, Spain), B. Ruíz-León (Córdoba, Spain)

**13:10**     **End**

Fri 20 Sep  
13:15 - 14:00

## Lunch

Break & Ceremony

**Fri 20 Sep**  
**14:00 - 15:00** | **Workshop session 2. Topic 4: Handling VIT adverse reactions**  
Room 0D Workshop Session

To know the tools to handle VIT adverse reactions to maintain patient's treatment.

Participants will be divided into 2 groups, and sessions will run simultaneously in rotation across 2 rooms, so each attendee will attend each of the session.

**14:00** | **Handling VIT adverse reactions**  
L. Marques (Lleida, Spain)

**14:25** | **Rotation for participants**

**14:30** | **Handling VIT adverse reactions**  
L. Marques (Lleida, Spain)

**Fri 20 Sep**  
**14:00 - 15:00** | **Workshop session 2. Topic 5: Risk factors in HVA**  
Room 3A Workshop Session

To approach the risk factors leading to HVA.

Participants will be divided into 2 groups, and sessions will run simultaneously in rotation across 2 rooms, so each attendee will attend each of the session.

**14:00** | **Risk factors in HVA**  
C. Breynaert (Leuven, Belgium)

**14:25** | **Rotation for participants**

**14:30** | **Risk factors in HVA**  
C. Breynaert (Leuven, Belgium)

**Fri 20 Sep**  
**15:00 - 15:30** | **Industry Session 3**  
Industry Session

**Fri 20 Sep**  
**15:30 - 16:00** | **Coffee Break**  
Break & Ceremony



Fri 20 Sep  
16:00 - 17:30

## Session IV: Insights in Hymenoptera venom allergy diagnosis and treatment

Room 0D Lecture session

Chair : D. González-Olano (Madrid, Spain), B.M. Bilò (Ancona, Italy)

To improve the knowledge of clinical, serological and genetic factors related to increased diagnostic accuracy and therapeutic efficacy.

**16:00 HVA and patient profile: diagnostic accuracy**

A. Vega Castro (Guadalajara, Spain)

**16:25 Sensitization profile and efficacy of VIT**

T. Jakob (Giessen, Germany)

**16:50 Cellular test for HVA: MAT and BAT**

P. Korosec (Golnik, Slovenia)

**17:15 Q&A**

Fri 20 Sep  
17:35 - 18:25

Group 1 – Topic (Diagnosis of Hymenoptera venom allergy)  
Poster Discussion

Chair : E. Boni (Bologna, Italy), D. González-Olano (Madrid, Spain)

17:35 P01 **The Role of Api m 5 in the Component Resolved Diagnosis for Hymenoptera Venom Allergy**

17:40 P02 **Investigation of the inhibitory effect of high allergen doses on basophils degranulation in patients allergic to Hymenoptera venom**

17:45 P03 **Variation of specific IgG and IgG4 to hymenoptera venoms during VIT induction**

17:50 P04 **Clinical and laboratory aspects in hornet's venom allergy: description of a cohort of 38 patients followed by Allergy Clinic in Ca' Foncello Hospital, Treviso**

17:55 P05 **Potential biomarkers to monitor early tolerance induction in hymenoptera venom based immunotherapy**

18:00 P06 **Analysis of relationships between wheal surface, specific IgE and age through machine learning in pre and post immunotherapy intradermal reactions**

18:05 P07 **The impact of the component-resolved diagnosis on venom immunotherapy prescription**

18:10 P08 **Sistemic Reaction To Wasp sting whith IgE deficiency**

18:15 P09 **Controversy in the application of a sting challenge test in a patient with presumed double venom hypersensitivity- a case report**

18:20 P10 **Utility of component-resolved diagnosis in venom immunotherapy qualification - a case report from a tertiary allergology centre**

Fri 20 Sep  
17:35 - 18:35

Group 2 – Topic (Hymenoptera venom immunotherapy)  
Poster Discussion

Chair : L. Marques (Lleida, Spain), B. Ruíz-León (Córdoba, Spain)

- 17:35**  
P11      **Safety of a 4-step ultra-rush induction protocol in wasp allergy**
- 
- 17:40**  
P12      **Safety Profile of Half-Day Ultra-Rush Hymenoptera Venom Immunotherapy Protocol in 22 Outpatients with Hymenoptera Venom Allergy**
- 
- 17:45**  
P13      **Modified ultrarush protocol efficacy and safety in hymenoptera venom immunotherapy**
- 
- 17:50**  
P14      **Hymenoptera Venom Immunotherapy with Ultra-Rush protocol: efficacy and safety of omalizumab pretreatment in patients with systemic reactions on previous Ultra-Rush**
- 
- 17:55**  
P15      **Api m 10 sensitization: does it matter?**
- 
- 18:00**  
P16      **Is it necessary to use a sistematically high dose of venom immunotherapy?**
- 
- 18:05**  
P17      **Hymenoptera venom allergy in patients aged from 4 to 18 years**
- 
- 18:10**  
P18      **Remember me? Recall urticaria at the site of the previous wasp sting occuring after venom immunotherapy - case report**
- 
- 18:15**  
P19      **Overcoming Challenges in Venom Immunotherapy: A Case Study of Successful Treatment in a 19-Year-Old Male with Severe Bee Sting Allergy**
- 
- 18:20**  
P20      **Rare Adverse Events in Rush Venom Immunotherapy: A Case of Rectal Pain and Delayed Dizziness**
- 
- 18:25**  
P21      **Efficacy of Venom Immunotherapy: A Case Series of Four Patients Treated for Bee Sting Hypersensitivity**
- 
- 18:30**  
P22      **A paediatric clinical case of bee venom allergy treated with venom immunotherapy**
-

Fri 20 Sep  
17:35 - 18:45

**Group 3 – Topic (Hymenoptera venom allergy and mast cell diseases)**  
Poster Discussion

Chair : P. Bonadonna (Verona, Italy), I. Alvarez Twose (Toledo, Spain)

- 17:35**  
P23 **Investigation of anaphylaxis in mastocytosis mouse models**
- 
- 17:40**  
P24 **Serum Tryptase Measurement at a University Hospital Center: Practices and Insights**
- 
- 17:45**  
P25 **MASTHAVE - a digital monitoring app designed for patients with mastocytosis**
- 
- 17:50**  
P26 **Molecular profile in Hymenoptera venom allergy in patients with Systemic Mastocytosis**
- 
- 17:55**  
P27 **Negative predictive value of the sting challenge in patients with mastocytosis: our experience**
- 
- 18:00**  
P28 **Pediatric mast cell disorders: be aware of tantrums**
- 
- 18:05**  
P29 **This poison flies**
- 
- 18:10**  
P30 **Systemic mastocytosis and non-steroidal anti-inflammatory drug-induced anaphylaxis: A case report**
- 
- 18:15**  
P31 **Severe Anaphylaxis Following Bee Sting with Slightly Elevated Basal Serum Tryptase: Could it be Mastocytosis?**
- 
- 18:20**  
P32 **The role of omalizumab on mastocytosis-associated symptoms**
- 
- 18:25**  
P33 **The allergist's central role in multidisciplinary care: from a hymenoptera sting to a mastocytosis diagnosis**
- 
- 18:30**  
P34 **Hymenoptera bite in professional botany, with subsequent diagnosis of systemic mastocytosis**
- 
- 18:35**  
P35 **Hymenoptera venom-associated anaphylaxis in a patient with indolent systemic mastocytosis without skin involvement**
- 
- 18:40**  
P36 **A Case of Recurrent Anaphylaxis and Flushing - Role of Biomarkers in Targeted Management**

Fri 20 Sep  
17:35 - 18:40

Group 4 – Topic (Hymenoptera in a changing world)  
Poster Discussion

Chair : T. Rama (Porto, Portugal), K. Spriggs (Parkville, Australia)

17:35  
P37 **Determining the safety of switching immunotherapy between different manufacturers in insect venom immunotherapy - a real-world experience**

17:40  
P38 **Hymenoptera venom allergy in Tolosaldea, Gipuzkoa, Spain: a retrospective and descriptive analysis of 15 patients**

17:45  
P39 **Hymenoptera venom antigen-specific immunotherapy: a 17-year-long experience of a Chilean center**

17:50  
P40 **Switching of venom preparation: do I have to fear?**

17:55  
P41 **Simultaneous immunotherapy initiation with two hymenoptera venoms: experience of 8 cases**

18:00  
P42 **Immunotherapy with *Vespa velutina nigrithorax*: two cases of successful ultra-rush induction protocol**

18:05  
P43 **A case of anaphylaxis from *Xylocopa violacea* sting**

18:10  
P44 **Efficacy and safety of hymenoptera venom allergy immunotherapy (VIT) and the longer maintenance schedule (12 months) in occupational exposed (OE) patients**

18:15  
P45 **Severe Adverse Reactions Following Interrupted Venom Immunotherapy in a 42-Year-Old Female Due to Product Unavailability: A Case Report**

18:20  
P46 **The prevalence of insect allergy in certain group of patient presented in "Ylli" polyclinic**

18:25  
P47 **Anaphylactic Reaction or Hymenoptera Poisoning?. Case Report**

18:30  
P48 **Anaphylactic Reaction to Hymenoptera Sting. Clinical Case Series**

18:35  
P49 **Adherence to Storage Conditions of Epinephrine Autoinjectors in Patients Undergoing Venom Immunotherapy: A Real-World Study**

📅 Saturday 21 September

EAACI Allergy School 2024

Sat 21 Sep  
**09:00 - 10:30** | **Session V: Insects in a Changing World**  
Room 0D Lecture session

Chair : T. Jakob (Giessen, Germany), F.J. Ortiz Sánchez (La Cañada (Almería), Spain)

To point out how to face the treatment in patients allergic to rare insects and the changing environmental factors influencing venom allergy. It also explores occupational aspects of the disease.

**09:00** **Rare and emerging insect allergy**  
K. Spriggs (Parkville, Australia)

**09:25** **Environmental factors (climate change, pollution...) and One Health Approach**  
A. Vega Castro (Guadalajara, Spain)

**09:50** **Bumblebee venom allergy as a model of occupational disease**  
C. Breynaert (Leuven, Belgium)

**10:15** **Q&A**

Sat 21 Sep  
**10:30 - 11:00** | **Coffee Break**  
Break & Ceremony

Sat 21 Sep  
**11:00 - 11:30** | **Oral Presentation Session 2**  
Room 0D Oral Abstract Session

Chair : L. Marques (Lleida, Spain), K. Spriggs (Parkville, Australia)

Best attendees' studies are chosen or exposed and discussed.

**11:00** **Study of the immune system changes during bee venom immunotherapy**  
OA4

**11:10** **Evaluation of the negative predictive value of the Sting Challenge Test**  
OA5

**11:20** **Vespa crabro venom: accuracy of common diagnostic tests**  
OA6

Sat 21 Sep  
11:30 - 13:40

## Session VI: Exploring the future of insect venom hypersensitivity

Room 0D Lecture session

Chair : P. Korosec (Golnik, Slovenia), G. Sturm (Graz, Austria)

A look into the future in managing various aspects of venom-allergic patients, promoting changes of action.

**11:30 Can we maintain the old epidemiological statements?**

B.M. Bilò (Ancona, Italy)

**11:55 Does sensitization equal HVA in mastocytosis patients?**

H. Oude Elberink (Haren, Netherlands)

**12:20 A sight on VIT protocols**

T. Alfaya Arias (Madrid, Spain)

**12:45 Mastocytosis: How to avoid the long road to diagnosis?**

T. Rama (Porto, Portugal)

**13:10 Q&A**

**13:25 Conclusions and closing**